BalducciL., BegheC.: The application of the principles of geriatrics to the management of the older person with cancer.Crit Rev Oncol Hematol, 35: 147–154, 2000.
2.
RepettoL., GranettoC., VenturinoA.: Prognostic evaluation of the older cancer patient. In: Comprehensive geriatric oncology, BalducciL, LymanGH, ErshlerWB Eds, Harwood Academic Publisher, Amsterdam, 287–300, 1998.
3.
RepettoL., FratinoL., AudisioR.A., VenturinoA., GianniW., VercelliM., ParodiS., Dal LagoD., GioiaF., MonfardiniS., AaproM.S., SerrainoD., ZagonelV.: Comprehensive geriatric assessment adds information to ECOG performance status in elderly cancer patients: a GIOGer study.J Clin Oncol, 20(2): 494–502, 2002.
4.
KemenyM.M., MussH.B., KornblithA.B., PetersonB., Judith WheelerJ., HarveyJ., CohenH.J.: Barriers to participation of older women with breast cancer in clinical trials.Proc Am Soc Clin Oncol, 19: 2371A, 2000.
5.
NortonL.: A Gompertzian model of human breast cancer growth.Cancer Res, 48: 7067–7071, 1988.
6.
SeidmanA.D., HudisC.A., AlbanelJ., TongW., TeplerI., CurrieV., MoynahanM.E., TheodoulouM., GollubM., BaselgaJ.M., NortonJ.: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatis breast cancer.J Clin Oncol, 16(10): 3353–3361, 1998.
7.
KlementG., KerbelR.: The concept of continuous low dose “metronomic” anti-angiogenic chemotherapy.Proc AACR, 048A, 2000.
8.
MilasL., HunterN.R., KurdogluB., MasonK.A., MeynR.E., StephensL.C., PetersL.J.: Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol.Cancer Chemother Pharmacol, 35: 297–303, 1995.
9.
LauD.H., XueL., YoungL.J., BurkeP.A., CheungA.T.: Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer.Cancer Biother Radiopharm, 14: 31–36, 1999.
10.
WangT., WangH., SoongY.: Paclitaxel-induced cell death: where the cell cycle and apoptosis come together.Cancer, 88(11): 2619–2628, 2000.
11.
MarkmanM.: Weekly paclitaxel in the management of ovarian cancer.Semin Oncol, 27(3 suppl 7): 37–40, 2000.
12.
Lopez de TeiadaM., CabreraL.T., IradiC.M., Toral PeñaJ.C., VilchezR.T., Garcia de LomasE., Blanco CastañoM.J., Bolaños DiazA.: Negative effects of breaks in therapy of advanced breast cancer treated with weekly paclitaxel.Proc Am Soc Clin Oncol, 19: 459A, 2000.
13.
MarchettiP., RonzinoG., RicevutoE., PorzioG., FicorellaC.: Somministrazione settimanale del paclitaxel: peculiarità e presupposti biologici.Tumori, 87: A1–A7, 2001.
14.
PerezE.A., VogelC.L., IrwinD.H., KirhnerJ.J., PatelR.: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer.J Clin Oncol, 19(22): 4216–4223, 2001.
15.
AsburyA., ChangA., BorosL., RubinsY., AsburyR.: Weekly moderate-dose paclitaxel (P) in advanced breast cancer (ABC).Proc Am Soc Clin Oncol, 17: 486A, 1998.
16.
GridelliC.: The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study.Oncologist, 6(suppl 1): 4–7, 2001.
17.
AndersonH., HopwoodP., StephensR.J., ThatcherN., CottierB., NicholsonM., MilroyR., MaughanT.S., FalkS.J., BondM.G., BurtP.A., ConnolyC.K., McIllmunayM.B., CarmichaelJ.: Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: a randomized trial with quality of life as the primary outcome.Br J Cancer, 83: 447–453, 2000.
18.
RansonM., DavidsonN., NicolsonM., FalkS., CarmichaelJ., LopezP., AndersonH., GustafsonN., JeynesA., GallantG., WashingtonT., ThatcherN.: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer.J Natl Cancer Inst, 92: 1074–1080, 2000.
19.
RoszkowskiK., PluzanskaA., KrzakowskiM., SmithA.P., SaigiE., AaseboU., ParisiA., Pham TranN., OlivaresR., BerilleJ.: A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).Lung Cancer, 27: 145–157, 2000.
20.
GridelliC., PerroneF., CigolariS., ManzioneL., PiantedosiF.V., BaberaS., PiazzaE., VinanteO., ClericiM., RobbiatiF., BertettoO., FrontiniL., SaccoC., IaffaioliR.V., GalloC.: The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase III trial: gemcitabine + vinorelbine vs vinorelbine and vs gemcitabine in elderly advanced NSCLC patients.Proc Am Soc Clin Oncol, 20: 1230A, 2001.
21.
ChangA., BorosL., AsburyR., RubinsJ., HuiL.: Weekly moderate-dose paclitaxel (P) in stage IV non-small cell lung cancer (NSCLC).Proc Am Soc Clin Oncol, 17: 1806A, 1998.
22.
AkerleyW.: Paclitaxel in advanced non-small cell lung cancer.An alternative high-dose weekly schedule: Chest, 17: 152S–155S, 2000.
23.
AkerleyW., HerndonJ., EgorinM.J.: CALGB 9731: phase II trial of weekly paclitaxel for advanced non-small cell lung cancer (NSCLC).Proc Am Soc Clin Oncol, 18: 1783A, 1999.
24.
FidiasP., SupkoJ., MartinsR.: A phase II clinical and pharmacokinetic study of weekly paclitaxel in elderly patients with non-small cell lung cancer.Lung Cancer, 29(Suppl 1): 184A, 2000.
25.
KoumakisG., DemiriM., BarbounisV., VassilomanolakisM., GontikakisE., PamouksoglouP., DahabreJ., EfremidisA.P.: Is weekly paclitaxel superior to paclitaxel given every three weeks?Lung Cancer, 35: 315–317, 2002.
26.
JuanO., AlberalaA., RocherA.: Phase II study of low dose weekly paclitaxel as second line treatment for advanced non-small cell lung cancer.Eur J Cancer, 37(suppl 6): 205A, 2001.
27.
BelaniC., BarstisJ., PerryM.: Phase II multicenter randomized trial of weekly paclitaxel (P) administered in combination with carboplatin (C) followed by maintenance P vs observation for patients with advanced and metastatic non-small cell lung cancer.Proc Am Soc Clin Oncol, 20: 1287A, 2001.
28.
KaernJ., TropèG., BaekelandtM.: Phase II trial of weekly single agent paclitaxel (P) in platinum (PLAT) and paclitaxel refractory ovarian cancer (OC).Proc Am Soc Clin Oncol, 20: 810A, 2001.
29.
BolanosM., BorregaP., Gonzales-BecaR.: Weekly paclitaxel/carboplatinum (P/CAR) as first-line chemotherapy in late relapses (LR) of epithelial ovarian cancer (OC). Preliminary results.Proc Am Soc Clin Oncol, 20: 870A, 2001.
